Eton Pharmaceuticals 宣布 ET-900 痉挛症治疗开发项目
Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Eton Pharmaceuticals 宣布启动 ET-900 开发项目，评估美卡舍明注射液用于治疗婴儿痉挛和癫痫性痉挛。公司已与贝勒医学院签署许可协议，涵盖胰岛素样生长因子 1（IGF-1）治疗痉挛相关的专利权；一项研究性新药申请已提交 FDA，拟开展针对难治性癫痫性痉挛儿童的研究者发起 II 期临床研究，目标于 2027 年第一季度开始入组和给药。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 2, 2026
Date of Report (Date of earliest event reported)
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
001-38738 |
37-1858472 |
|
(State of |
(Commission |
(I.R.S. Employer |
|
incorporation) |
File Number) |
Identification Number) |
|
21925 W. Field Parkway, Suite 235 |
|
Deer Park, Illinois 60010-7278 |
|
(Address of principal executive offices) (Zip code) |
|
(847) 787-7361 |
|
(Registrant’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
||
|
Common Stock, par value $0.001 per share |
ETON |
NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01: Other Events
On November 2, 2026, Eton Pharmaceuticals, Inc. (the “Company”) announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. The Company has entered into a license agreement with Baylor College of Medicine covering patent rights related to the use of insulin-like growth factor 1 (IGF-1) for the treatment of spasms. A research Investigational New Drug application has been submitted to the U.S. Food and Drug Administration for an investigator-sponsored Phase 2 clinical study evaluating mecasermin in children with refractory epileptic spasms, with initial enrollment and patient dosing targeted for the first quarter of 2027.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
2
Item 9.01: Financial Statements and Exhibits
|
Exhibit No. |
Description |
|
| Exhibit 99.1 | Press Release dated November 2, 2026 | |
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: November 2, 2026 |
By: |
/s/ Judith M. Matthews |
|
Judith M. Matthews |
||
|
Chief Financial Officer and Secretary |
||
|
(Principal Financial Officer) |
4
来源：SEC EDGAR · 本站存档